CSPG4P12

Across TCGA pan-cancer cohorts, CSPG4P12 RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated CSPG4P12 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CSPG4P12 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated CSPG4P12 expression acts as an unfavorable survival marker, although some lineages such as READ and LGG show a favorable association.

LIHC, READ, and LGG are the cancer types where CSPG4P12 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.314	0.529	<.001	70	view →
READ	DFS	Quartile	II,III,IV	0.980	0.555	<.001	26	view →
LGG	DFS	Tertile	All	0.824	0.665	.009	20	view →
THCA	DFS	Median	IV	0.409	0.767	.019	19	view →
KIRC	DFS	Median	All	0.737	0.855	.009	16	view →
UVM	OS	Tertile	III,IV	0.452	0.879	.034	14	view →
ACC	DFS	Quartile	All	0.447	0.763	.007	13	view →
CHOL	DFS	Quartile	All	0.745	0.075	.019	6	view →
BLCA	DFS	Median	All	0.389	0.299	.019	6	view →
LUSC	DFS	Median	III,IV	0.452	0.810	.044	6	view →
PCPG	DFS	Quartile	All	0.511	0.919	.003	5	view →
STAD	DFS	Median	III,IV	0.720	0.471	.011	4	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 17 lineages.

CSPG4P12–LIHC (DFS)

Open the LIHC breakdown →